185 related articles for article (PubMed ID: 31851762)
1. Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric Fanconi anaemia patients.
van Hoogdalem MW; Emoto C; Fukuda T; Mizuno T; Mehta PA; Vinks AA
Br J Clin Pharmacol; 2020 May; 86(5):933-943. PubMed ID: 31851762
[TBL] [Abstract][Full Text] [Related]
2. Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different?
Mehta PA; Emoto C; Fukuda T; Seyboth B; Teusink-Cross A; Davies SM; Wilhelm J; Fuller K; Vinks AA; Boulad F
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2416-2421. PubMed ID: 31326610
[TBL] [Abstract][Full Text] [Related]
3. Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study.
Mehta PA; Davies SM; Leemhuis T; Myers K; Kernan NA; Prockop SE; Scaradavou A; O'Reilly RJ; Williams DA; Lehmann L; Guinan E; Margolis D; Baker KS; Lane A; Boulad F
Blood; 2017 Apr; 129(16):2308-2315. PubMed ID: 28179273
[TBL] [Abstract][Full Text] [Related]
4. Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization.
McCune JS; Bemer MJ; Barrett JS; Scott Baker K; Gamis AS; Holford NH
Clin Cancer Res; 2014 Feb; 20(3):754-63. PubMed ID: 24218510
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients.
Willcox A; Wong E; Nath C; Janson B; Harrison SJ; Hoyt R; Bajel A; Shaw P; Ritchie D; Grigg A
Ann Hematol; 2018 Dec; 97(12):2509-2518. PubMed ID: 30051172
[TBL] [Abstract][Full Text] [Related]
6. Utilization of a Population Pharmacokinetic Model to Improve a Busulfan Test-Dose Strategy in Allogeneic Hematopoietic Cell Transplant Recipients.
Dunlap TC; Weiner DL; Kemper RM; Kardouh M; DeVane SC; Symonds A; Shaw JR; Armistead PM; Ptachcinski JR; Crona DJ
J Clin Pharmacol; 2023 Sep; 63(9):1026-1035. PubMed ID: 37122163
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a Test Dose Strategy for Pharmacokinetically-Guided Busulfan Dosing for Hematopoietic Stem Cell Transplantation.
Davis JM; Ivanova A; Chung Y; Shaw JR; Rao KV; Ptachcinski JR; Sharf AA; Serody JS; Armistead PM; Wood WA; Coghill JM; Jamieson KJ; Vincent BG; Riches ML; Shea TC; Alexander MD
Biol Blood Marrow Transplant; 2019 Feb; 25(2):391-397. PubMed ID: 30244102
[TBL] [Abstract][Full Text] [Related]
8. Busulfan dose Recommendation in Inherited Metabolic Disorders: Population Pharmacokinetic Analysis.
Takahashi T; Illamola SM; Jennissen CA; Long SE; Lund TC; Orchard PJ; Gupta AO; Long-Boyle JR
Transplant Cell Ther; 2022 Feb; 28(2):104.e1-104.e7. PubMed ID: 34883294
[TBL] [Abstract][Full Text] [Related]
9. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
Rhee SJ; Lee JW; Yu KS; Hong KT; Choi JY; Hong CR; Park KD; Shin HY; Song SH; Kang HJ; Lee H
Am J Hematol; 2017 Jul; 92(7):607-613. PubMed ID: 28370238
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use.
Long-Boyle JR; Savic R; Yan S; Bartelink I; Musick L; French D; Law J; Horn B; Cowan MJ; Dvorak CC
Ther Drug Monit; 2015 Apr; 37(2):236-45. PubMed ID: 25162216
[TBL] [Abstract][Full Text] [Related]
11. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.
Bartelink IH; Boelens JJ; Bredius RG; Egberts AC; Wang C; Bierings MB; Shaw PJ; Nath CE; Hempel G; Zwaveling J; Danhof M; Knibbe CA
Clin Pharmacokinet; 2012 May; 51(5):331-45. PubMed ID: 22455797
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation.
van der Stoep MYEC; Zwaveling J; Bertaina A; Locatelli F; Guchelaar HJ; Lankester AC; Moes DJAR
Br J Clin Pharmacol; 2019 Sep; 85(9):2033-2044. PubMed ID: 31144349
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of treosulfan cumulative exposure in paediatric patients through population pharmacokinetics and dosing simulations.
Rosser SPA; Lee S; Kohli S; Keogh SJ; Chung J; O'Brien T; Fraser C; McLachlan AJ; Shaw PJ; Nath CE
Br J Clin Pharmacol; 2023 Apr; 89(4):1413-1424. PubMed ID: 36369677
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients.
Booth BP; Rahman A; Dagher R; Griebel D; Lennon S; Fuller D; Sahajwalla C; Mehta M; Gobburu JV
J Clin Pharmacol; 2007 Jan; 47(1):101-11. PubMed ID: 17192508
[TBL] [Abstract][Full Text] [Related]
15. Busulfan dosing in children with BMIs ≥ 85% undergoing HSCT: a new optimal strategy.
Browning B; Thormann K; Donaldson A; Halverson T; Shinkle M; Kletzel M
Biol Blood Marrow Transplant; 2011 Sep; 17(9):1383-8. PubMed ID: 21288495
[TBL] [Abstract][Full Text] [Related]
16. Predictive performance of a busulfan pharmacokinetic model in children and young adults.
Bartelink IH; van Kesteren C; Boelens JJ; Egberts TC; Bierings MB; Cuvelier GD; Wynn RF; Slatter MA; Chiesa R; Danhof M; Knibbe CA
Ther Drug Monit; 2012 Oct; 34(5):574-83. PubMed ID: 22972539
[TBL] [Abstract][Full Text] [Related]
17. Model-informed precision dosing for alemtuzumab in paediatric and young adult patients undergoing allogeneic haematopoietic cell transplantation.
Dong M; Emoto C; Fukuda T; Arnold DE; Mehta PA; Marsh RA; Vinks AA
Br J Clin Pharmacol; 2022 Jan; 88(1):248-259. PubMed ID: 34182590
[TBL] [Abstract][Full Text] [Related]
18. Personalized pharmacokinetic targeting with busulfan in allogeneic hematopoietic stem cell transplantation in infants with acute lymphoblastic leukemia.
Takachi T; Arakawa Y; Nakamura H; Watanabe T; Aoki Y; Ohshima J; Takahashi Y; Hirayama M; Miyamura T; Sugita K; Koh K; Horibe K; Ishii E; Mizutani S; Tomizawa D
Int J Hematol; 2019 Sep; 110(3):355-363. PubMed ID: 31201644
[TBL] [Abstract][Full Text] [Related]
19. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
[TBL] [Abstract][Full Text] [Related]
20. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.
Nguyen L; Leger F; Lennon S; Puozzo C
Cancer Chemother Pharmacol; 2006 Jan; 57(2):191-8. PubMed ID: 16133536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
